Skip to content
DataLookout
Menu

LINKER-MM5NCT07222761

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 15 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 53 → 60 locations
  2. Minor Trial sites expanded: 44 → 53 locations
  3. Minor Trial sites expanded: 39 → 44 locations
  4. Minor Trial sites expanded: 28 → 39 locations
  5. Notable Eligibility criteria expanded, about 7 words
    • Trial sites expanded: 24 → 28 locations
    • Secondary endpoints: details revised at 4 of 36 entries
  6. Minor Trial sites expanded: 20 → 24 locationsv10
  7. Minor Trial sites expanded: 16 → 20 locationsv9
  8. Minor Primary completion date: Jun 15, 2029 to May 21, 2029
    • Study completion date: Sep 17, 2034 to Aug 23, 2034
    v8
  9. Minor Study sites: 14 to 16v7
  10. Minor Study sites: 13 to 14v6
  11. Minor Trial sites expanded: 9 → 13 locationsv5
  12. Minor Study sites: 3 to 9v4
  13. Minor Study sites: 2 to 3v3
  14. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 2
    • Primary completion date: Jun 18, 2029 to Jun 15, 2029
    • Study completion date: Sep 20, 2034 to Sep 17, 2034
    • Start date changed from estimate of Jan 29, 2026 to Jan 2, 2026
  15. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Occurrence of Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to 5 years
Severity of TEAEs
Timeframe: Up to 5 years
Occurrence of Adverse Events of Special Interest (AESI)
Timeframe: Up to 5 years
Severity of AESIs
Timeframe: Up to 5 years
Occurrence of Serious Adverse Events (SAEs)
Timeframe: Up to 5 years
Severity of SAEs
Timeframe: Up to 5 years
Minimal Residual Disease (MRD)-negative Complete Response (CR)
Timeframe: At 12 months
Progression-Free Survival (PFS) per IMWG response criteria as determined by BIRC
Timeframe: Up to 5 years

Secondary (36)

Occurrence of grade ≥2 Cytokine Release Syndrome (CRS)
Timing of grade ≥2 CRS
Overall Survival (OS)
Achievement of Partial Response (PR) or better per IMWG response criteria as determined by BIRC
Achievement of Very Good Partial Response (VGPR) or better per IMWG response criteria as determined by BIRC
Show 31 moreShow less
Achievement of CR or better per IMWG response criteria as determined by BIRC
Duration Of Response (DOR) as per IMWG response criteria
Time To Progression (TTP) as per IMWG response criteria
Time To Next Treatment (TTNT)
Second PFS
MRD-negative CR criteria at any time
Time to PR IMWG response category
Time to VGPR IMWG response category
Time to CR IMWG response category
Time to stringent Complete Response (sCR) IMWG response category
Sustained MRD-negative CR
Duration of MRD-negative CR
Occurrence of TEAEs
Severity of TEAEs
Occurrence of AESIs
Severity of AESIs
Occurrence of SAEs
Severity of SAEs
Concentrations of linvoseltamab in serum over time
Incidence of Antidrug Antibodies (ADAs) to linvoseltamab
Magnitude of ADAs to linvoseltamab
Concentrations total soluble B-cell Maturation Antigen (sBCMA) in serum over time
Change from baseline in Global Health Status (GHS)/Quality of Life (QoL), per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Change from baseline in Physical Functioning (PF), per EORTC QLQ-C30
Change from baseline in Role Functioning (RF), per EORTC QLQ-C30
Change from baseline in pain, per EORTC QLQ-C30
Change from baseline in fatigue, per EORTC QLQ-C30
Change in patient reported Disease Symptoms (DS) per EORTC Quality of Life Questionnaire-Multiple Myeloma (MM) module 20 [QLQ-MY20])
Change in patient reported Treatment Side Effects (TSE) per EORTC QLQ-MY20
Change in patient-reported health state per EuroQoL-5 Dimension-5 Level Scale [EQ-5D-5L]) Visual Analogue Scale (VAS)
Change in patient-reported overall impact of treatment per Functional Assessment of Chronic Illness Therapy (FACIT) item GP5

Arms and interventions

Part 1: Arm AExperimental
Part 1: Arm BExperimental
Part 2: Arm AExperimental
Part 2: Arm BExperimental
Part 2: Arm CExperimental

Drugs: Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib

Sites

60 sites in 9 countries

Brazil 10, United Kingdom 9, Australia 8, South Korea 7, United States 7, Taiwan 6, Chile 5, Turkey (Türkiye) 5, Japan 3